Carlos Mayo

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · Annals of Oncology · 2018 · 22 citations · Full text

Medicine, Oncology, Pharmacology +12

An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer

David R. Spigel, Alexander Luft, H. Depenbrock et al. · Clinical Lung Cancer · 2017 · 19 citations

Medicine, Oncology, Pharmacology +15

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

R. Rosell, Matias Molina, Camila Mendes Costa et al. · Journal of Clinical Oncology · 2010 · 14 citations

Medicine, Oncology, Pharmacology +15

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere

Heloisa P. Soares, Soley Bayraktar, Marcelo Blaya et al. · Cancer Chemotherapy and Pharmacology · 2014 · 13 citations

Medicine, Oncology, Pharmacology +14